Gilead and Lyndra co-develop long-acting HIV therapies

By Vassia Barba

- Last updated on GMT

(Image: Getty/Marchmeena29)
(Image: Getty/Marchmeena29)

Related tags: Gilead, Lyndra Therapeutics, Hiv

Following Gilead’s funding of Lyndra’s technology, the latter company offers exclusive rights to its therapeutics platform for long-acting HIV therapies formulations.

The partnership between the two companies began when Gilead Sciences joined Lyndra Therapeutics' $55m (€49m) Series B financing round in January 2019​, along with the Bill & Melinda Gates Foundation and other organisations. 

The two companies have now announced a collaboration, under which they will work together to develop and commercialize oral HIV therapies, with Gilead gaining exclusive rights to Lyndra’s therapeutics platform for long-acting formulations.

Speaking about “potential strategies for long-acting regimens that would reduce pill burden”​, Gilead’s CSO, John McHutchison said that “this early partnership is the latest step in our ongoing investment in HIV research and development.”

Lyndra’s star-shaped pill

Lyndra Therapeutics, a Massachusetts, US-based MIT spin-out, has designed a capsule in a star-shaped formulation, which opens once inside the stomach, releasing active pharmaceutical ingredients (APIs) consistently over time before exiting via the gastrointestinal tract.

This orally administered dosage form aims to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach.

By turning daily treatments into weekly or monthly doses, the formulation is expected to reduce side-effects and healthcare costs while improving medication adherence and drug efficacy.

Related news

Show more

Related products

show more

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Spray Dried Powders for High Dose Drug Delivery

Spray Dried Powders for High Dose Drug Delivery

Catalent | 01-Feb-2022 | Product Presentation

This Catalent webinar will explore how spray dried particles provide an attractive, carrier-free option for highly dispersed delivery of API to deep lung...

Related suppliers

Follow us

Products

View more

Webinars